Outcome and Pathologic Classification of Children and Adolescents with Mediastinal Large B-cell Lymphoma Treated with FAB/LMB96 Mature B-NHL Therapy

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2012 Nov 15

PMID 23149845

Citations 32

Authors

Mary Gerrard

Ian M Waxman

Richard Sposto

Anne Auperin

Sherrie L Perkins

Stanton Goldman

Lauren Harrison

Ross Pinkerton

Keith McCarthy

Martine Raphael

Catherine Patte

Mitchell S Cairo

Affiliations

Soon will be listed here.

Abstract

Mediastinal large B-cell lymphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients ≤ 18 years of age. We analyzed data from childhood and adolescent patients with stage III MLBL (n = 42) and non-MLBL DLBCL (n = 69) treated with Group B therapy in the French-American-British/Lymphome Malins de Burkitt (FAB/LMB) 96 study. MLBL patients had a male/female 26/16; median age, 15.7 years (range, 12.5-19.7); and LDH < 2 versus ≥ 2 × the upper limit of normal, 23:19. Six MLBL patients (14%) had < a 20% response to initial COP (cyclophosphamide, vincristine, and prednisone) therapy. Central pathology revealed approximately 50% with classical features of primary MLBL. Five-year event-free survival for the stage III MLBL and non-MLBL DLBCL groups was 66% (95% confidence interval [CI], 49%-78%) and 85% (95% CI, 71%-92%), respectively (P < .001; 14%). The 5-year overall survival in the 42 MLBL patients was 73% (95% CI, 56%-84%). We conclude that MLBL in adolescent patients is associated with significantly inferior event-free survival compared with stage III non-MLBL DLBCL and can be of multiple histologies. Alternate treatment strategies should be investigated in the future taking into account both adult MLBL approaches and more recent biologic findings in adult MLBL.

Citing Articles

Real-World Data on Lymphoma in Adolescents and Young Adults (AYA)-Report From the Lymphoma and Related Diseases Registry (LaRDR).

Wong E, Wellard C, Ng J, Chung E, McQuilten Z, Opat S EJHaem. 2025; 6(1):e1096.

PMID: 39886099 PMC: 11781129. DOI: 10.1002/jha2.1096.

Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with a FAB/ LMB-based chemotherapy regimen with rituximab.

Dourthe M, Auperin A, Rigaud C, Barbati M, Bonneau J, Buchbinder N Haematologica. 2024; 109(11):3790-3794.

PMID: 38988265 PMC: 11532712. DOI: 10.3324/haematol.2024.285403.

Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients.

Cook M, Williams L, Dorris C, Luo Y, Makambi K, Dunleavy K Haematologica. 2023; 109(3):846-856.

PMID: 37646662 PMC: 10905081. DOI: 10.3324/haematol.2023.283446.

Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.

El-Mallawany N, Alexander S, Fluchel M, Hayashi R, Lowe E, Giulino-Roth L Pediatr Blood Cancer. 2023; 70 Suppl 6:e30565.

PMID: 37449925 PMC: 10577684. DOI: 10.1002/pbc.30565.

Malignant Tracheoparenchymal Fistula in Primary Mediastinal B-Cell lymphoma detected on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Singh V, Ora M, Gambhir S Indian J Nucl Med. 2023; 37(4):367-369.

PMID: 36817202 PMC: 9930462. DOI: 10.4103/ijnm.ijnm_40_22.

References

MURPHY S . Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980; 7(3):332-9. View

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

Moller P, Lammler B, Herrmann B, Otto H, Moldenhauer G, Momburg F . The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. Immunology. 1986; 59(3):411-7. PMC: 1453200. View

Todeschini G, SECCHI S, Morra E, Vitolo U, Orlandi E, Pasini F . Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004; 90(2):372-6. PMC: 2409547. DOI: 10.1038/sj.bjc.6601460. View

Seidemann K, Tiemann M, Lauterbach I, Mann G, Simonitsch I, Stankewitz K . Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group. J Clin Oncol. 2003; 21(9):1782-9. DOI: 10.1200/JCO.2003.08.151. View

Green M, Monti S, Rodig S, Juszczynski P, Currie T, ODonnell E . Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-77. PMC: 2995356. DOI: 10.1182/blood-2010-05-282780. View

Steidl C, Shah S, Woolcock B, Rui L, Kawahara M, Farinha P . MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011; 471(7338):377-81. PMC: 3902849. DOI: 10.1038/nature09754. View

Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais J . Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood. 2009; 114(6):1236-42. PMC: 2824656. DOI: 10.1182/blood-2009-03-209759. View

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(4):235-42. DOI: 10.1056/NEJMoa011795. View

10.

Roberts R, Wright G, Rosenwald A, Jaramillo M, Grogan T, Miller T . Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood. 2006; 108(1):311-8. PMC: 1895840. DOI: 10.1182/blood-2005-11-4742. View

11.

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7(5):379-91. DOI: 10.1016/S1470-2045(06)70664-7. View

12.

Oschlies I, Burkhardt B, Salaverria I, Rosenwald A, DAmore E, Szczepanowski M . Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica. 2010; 96(2):262-8. PMC: 3031694. DOI: 10.3324/haematol.2010.030809. View

13.

Copie-Bergman C, Gaulard P, Maouche-Chretien L, Briere J, Haioun C, Alonso M . The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999; 94(10):3567-75. View

14.

Savage K . Rare B-cell lymphomas: primary mediastinal, intravascular, and primary effusion lymphoma. Cancer Treat Res. 2008; 142:243-64. DOI: 10.1007/978-0-387-73744-7_10. View

15.

Cairo M, Gerrard M, Sposto R, Auperin A, Pinkerton C, Michon J . Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2006; 109(7):2736-43. PMC: 1852225. DOI: 10.1182/blood-2006-07-036665. View

16.

Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J . Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2010; 22(3):664-670. DOI: 10.1093/annonc/mdq418. View

17.

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R . Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6):851-62. PMC: 2194208. DOI: 10.1084/jem.20031074. View

18.

Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland M, Le Gouvello S, Gaulard P . Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004; 104(2):543-9. DOI: 10.1182/blood-2003-10-3545. View

19.

Hochberg J, Waxman I, Kelly K, Morris E, Cairo M . Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2008; 144(1):24-40. DOI: 10.1111/j.1365-2141.2008.07393.x. View

20.

Steidl C, Gascoyne R . The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011; 118(10):2659-69. DOI: 10.1182/blood-2011-05-326538. View